Effectiveness of positron emission tomography for the detection of melanoma metastases

Annals of Surgery

Volumn 227, Issue 5, 1998, Pages 764-771

  Holder Jr , Walter D ^a   White Jr , Richard L ^a   Zuger, James H ^a   Easton Jr , Edward J ^a   Greene, Frederick L ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BREAST CANCER; BRONCHUS CANCER; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CYTOLOGY; DATA ANALYSIS; ENDOMETRIOSIS; EXCISION; FEMALE; GRANULOMA; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LEIOMYOMA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WARTHIN TUMOR;

DIAGNOSTIC ERRORS; FLUORODEOXYGLUCOSE F18; HUMANS; MELANOMA; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0345019880     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199805000-00017     Document Type: Conference Paper

References (28)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1996. CA Cancer J Clin 1996; 46:5-28.
2. Balch CM, Soong SL, Murad TM, et al. A multifactoral analysis of melanoma. III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981; 193:377-388.
3. Reintgen DR, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patient with malignant melanoma. Ann Surg 1997; 225:1-14.
4. Larson SM, Weiden PL, Grunbaum Z, et al. Positron imaging feasibility studies. II: Characteristics of 2-deoxyglucose uptake in rodent and canine neoplasms [concise communication]. J Nucl Med 1981; 22:875.
5. Gupta NC, Frick MP. Clinical applications of positron emission tomography in cancer. CA Cancer J Clin 1993; 43:235-254.
6. ' 6. Meikles R, Dahlbum M: Positron emission tomography. In Murray PC, Ell PJ, eds. Nuclear Medicine In Clinical Diagnosis and Treatment. Edinburgh: Churchill-Livingstone; 1994:1327.
7. 18F] fluorodeoxyglucose. Ann Thorac Surg 1994; 58:698-703.
8. Bailet JW, Abemayor E, Jabour BA, et al. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992; 102:281-288.
9. Schiepers C, Penninckx F, DeVadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995; 21:517-522.
10. Lapela M, Leskinen S. Minn HRI, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine- 18-fluorodeoxyglucose. Blood 1995; 86: 3522-3527.
11. Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996; 88:1204-1209.
12. 18fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992; 33:333-339.
13. 18F fluorodeoxyglucose: comparison with CT and US. Radiology 1995; 195:345-352.
14. 18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993; 51:175-181.
15. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated analog, 2-fluoro-2-deoxy-D-glucose (F18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21:670-675.
16. 18fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993; 34:1420-1407.
17. Macfarlane DJ, Sondak V, Wahl RL. Initial prospective evaluation of FDG-PET in staging regional lymph nodes in patients with cutaneous malignant melanoma (CMM). J Nucl Med 1995; 36:116P.
18. 18F]-fluoro-2-deoxy-D-glucose. Radiology 1995; 195:705-709.
19. Damian DL, Fulham MJ, Thompson E, Thompson J. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996; 6:325-329.
20. Wagner JD, Schauwecker D, Hutchins G, Coleman JJ. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997; 64:181-189.
21. 18F] fluoride. Int J Rad Appl Instrum A 1988; 39:699-703.
22. Sasaki M, Ichiya Y, Kuwabara Y, et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with x-ray computed tomography. Eur J Nucl Med 1996; 23:741-747.
23. Scott WJ, Gobar LS, Terry JD, et al. Mediastinal lymph node staging of non-small cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996; 111:642-648.
24. White PG, Adams H, Crane MD, Butchart EG. Preoperative staging of carcinoma of the bronchus: can computed tomographic scanning reliably identify stage III tumors? Thorax 1994; 49:951-957.
25. Primack SL, Lee KS, Logan PM, et al. Brochogenic carcinoma: utility of CT in the evaluation of patients with suspected lesions. Radiology 1994; 193:795-800.
26. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996; 171:21-26.
27. Gupta N, Bowman B. PET FDG imagery for follow-up evaluation of colorectal cancer. Radiology 1991; 199:181-185.
28. Wagner JD, Schauwecker D, Hutchins G, Coleman JJ. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997; 64:181-189.